NewAmsterdam Pharma Co. NV (NAMS)
30.18
+0.85
(+2.90%)
USD |
NASDAQ |
Jun 11, 13:35
NewAmsterdam Pharma Shareholders Equity (Quarterly) : 665.22M for March 31, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 665.22M |
| December 31, 2025 | 683.43M |
| September 30, 2025 | 728.07M |
| June 30, 2025 | 778.50M |
| March 31, 2025 | 777.36M |
| December 31, 2024 | 757.50M |
| September 30, 2024 | 378.86M |
| June 30, 2024 | 387.44M |
| March 31, 2024 | 411.80M |
| Date | Value |
|---|---|
| September 30, 2022 | 127.07M |
| June 30, 2022 | 131.85M |
| March 31, 2022 | 133.03M |
| December 31, 2021 | 131.64M |
| September 30, 2021 | 130.71M |
| June 30, 2021 | 128.98M |
| March 31, 2021 | 130.28M |
| December 31, 2020 | 127.46M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ProQR Therapeutics NV | 43.32M |
| Pharming Group NV | 268.96M |
| Damora Therapeutics, Inc. | 510.26M |
| Dyne Therapeutics, Inc. | 865.06M |
| ACADIA Pharmaceuticals, Inc. | 1.248B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 732.64M |
| Total Liabilities (Quarterly) | 67.42M |
| Current Ratio | 9.760 |
| Net Debt Paydown Yield | 0.00% |